Pregnancy after cancer: more births among survivors, but delivery needs careful planning
A study published on 16 November 2026 in JAMA Network Open analysed more than 28 million hospital deliveries in the United States. The overall picture is largely reassuring: women who have survived cancer are giving birth more often, and most carry their pregnancy to term. At delivery, however, they face a higher risk of severe complications, which is why the authors recommend planning pregnancy together with an experienced team.
Background
Thanks to better treatment, the number of women of reproductive age who survive cancer keeps growing. Fertility preservation (freezing of oocytes, embryos or ovarian tissue) and assisted reproduction are also more widely available. Many of these women wish to become pregnant, yet data on how deliveries go for former cancer patients have so far been limited.
The authors distinguish two groups:
• past cancer survivors: women with a history of cancer and no active disease
• current cancer survivors: women with active cancer at the time of delivery
The study
• Led by Koji Matsuo (University of Southern California) with colleagues from the University of Osaka
• Data from the National Inpatient Sample, a large US national database of hospital admissions, from 2016 to 2023
• 28,360,443 hospital deliveries: 106,740 (0.4%) in past cancer survivors and 21,975 (less than 0.1%) in women with current cancer
• Median age at delivery: 33 years in past survivors versus 29 years in women without cancer
• Most frequent previous cancers: thyroid (22.3%), melanoma (15.7%), breast (11.7%), lymphoma (10.8%), cervix (6.6%), leukaemia (4.2%), ovary (3.6%)
The results
• Deliveries among past cancer survivors rose from 30.1 to 45.6 per 10,000 deliveries, an increase of about 50% over eight years; deliveries in women with current cancer remained stable (7.0 to 7.4)
• 57.6% of past survivors delivered at 39 weeks or later, close to the figure for women without cancer (60.4%); among women with current cancer the proportion fell to 39.6%
• Caesarean delivery was more common: 38% in past survivors versus 32.4% in women without cancer
• Severe maternal morbidity (for example cardiac arrest, embolism, shock, sepsis, acute kidney failure, disseminated intravascular coagulation) occurred in 11.9 per 1,000 deliveries among past survivors versus 6.8 per 1,000 in women without cancer: a risk about 45% higher after adjustment for age, comorbidities and other characteristics
• The risk was much higher in women with current cancer: 48.2 severe complications per 1,000 deliveries, roughly four times the rate in women without cancer
• In past survivors, in-hospital maternal mortality was not significantly increased
• In exploratory analyses by cancer type, the risk was highest after leukaemia and lymphoma, intermediate after breast, cervical and thyroid cancer, and not significantly increased after melanoma
What it means for patients and laboratory testing
The study does not say that pregnancy after cancer should be discouraged: it says it should be prepared. The authors stress the importance of preconception evaluation and, where needed, early referral to centres with multidisciplinary teams (oncologist, maternal-fetal medicine specialist, cardiologist, anaesthetist).
Laboratory tests play a concrete role in this process, to be decided case by case with the doctor:
• the basic tests of the pregnancy check-up, starting with the full blood count (see the page on blood) and ferritin, since some cancer treatments can leave effects on the bone marrow
• thyroid function, particularly relevant for women treated for thyroid cancer, the most frequent cancer in the study (see thyroid check-up)
• assessment of ovarian reserve with anti-Müllerian hormone (AMH) and FSH, because chemotherapy and radiotherapy can reduce it even when menstrual cycles have returned
• after conception, routine pregnancy monitoring, starting with beta-hCG
Who it concerns
• Cancer survivors who wish to become pregnant, and their partners
• Young women about to start cancer treatment who must decide on fertility preservation
• General practitioners, gynaecologists, oncologists and fertility centres
Limitations
• It is a cross-sectional study of administrative data: it shows associations, not cause and effect
• Diagnoses are based on hospital discharge codes that were not validated against medical records
• There is no information on cancer stage, treatments received, time since remission or use of assisted reproduction
• The unit of analysis is the delivery, not the woman: women with more than one delivery are counted more than once
• Only events occurring during the delivery admission are captured
• The data refer to the United States and cannot be directly transferred to other countries; results by cancer type are exploratory
In summary
• In the US, deliveries among cancer survivors increased by about 50% between 2016 and 2023
• Nearly 6 in 10 past survivors deliver at term, similar to other women
• The risk of severe complications at delivery is higher (11.9 versus 6.8 per 1,000) but remains low in absolute terms
• The risk is much higher when cancer is still active
• Preconception evaluation, with the tests chosen by the doctor, helps plan pregnancy and delivery safely
Sources:
Matsuo K et al., JAMA Network Open, 16 November 2026; PubMed; Oncology Nurse Advisor; CURE
Laboratory tests:
AMH – Ormone anti mulleriano, FSH, Beta-HCG, Ferritina, Sangue – emocromo, Check-Up Tiroide, Check-Up Endocrinologico
Diseases, symptoms and related pages:
Check-Up Gravidanza, Check-Up Donna, Endocrinologia, Tumore ovarico: un esame del sangue per le lesioni che lo precedono, Risonanza magnetica o mammografia?, Terapia CAR-T














































Discussion about this post